Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 16/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.49 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.49 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.49 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775218 | 1.00 | MTOR (0.55) | MTORCYP3A4PIK3CAKCNH2RICTOR | |
| SCHEMBL2724864 | 0.89 | MTOR (0.54) | MTORCYP3A4PIK3CAKCNH2RPTOR | |
| SCHEMBL2724867 | 0.89 | MTOR (0.54) | MTORCYP3A4PIK3CAKCNH2RPTOR | |
| SCHEMBL3773107 | 0.88 | MTOR (0.71) | MTORCYP3A4PIK3CAKCNH2RICTOR | |
| SCHEMBL3773104 | 0.88 | MTOR (0.71) | MTORCYP3A4PIK3CAKCNH2RICTOR | |
| SCHEMBL2726024 | 0.88 | MTOR (0.48) | MTORPIK3CA | |
| SCHEMBL2724926 | 0.88 | MTOR (0.59) | MTORCYP3A4PIK3CAKCNH2RICTOR | |
| SCHEMBL2724923 | 0.88 | MTOR (0.59) | MTORCYP3A4PIK3CAKCNH2RICTOR | |
| SCHEMBL2725450 | 0.86 | MTOR (0.71) | MTORCYP3A4PIK3CAKCNH2RICTOR | |
| SCHEMBL2725448 | 0.86 | MTOR (0.71) | MTORCYP3A4PIK3CAKCNH2RICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | claimed |
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | MTOR 1/4885CYP3A4 1146/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.